1. Brazil Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Profarma Distribuidora de Produtos Farmaceuticos SA

Profarma Distribuidora de Produtos Farmaceuticos SA

9.35
BRL
-0.01
(-0.11%)
1.31EPS
5.40P/E
833.75MMarket Cap
Profarma Distribuidora de Produtos Farmaceuticos SA
B3:PFRM3
(B3)

Recent

price

9.35

P/E

ratio

5.40

div

yld

3.40%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
BRL
86.46
80.64
90.99
96
78.32
79.19
68.57
52.23
36.46
39.16
44.71
52.31
63.75
70.64
82.81
93.39
101.86
Revenue per Share
0.95
0.73
1.14
0.56
-1.18
-0.48
-0.82
-1.44
-0.08
0.1
0.43
0.64
0.66
0.57
0.93
0.97
1.26
Basic EPS, GAAP
1.01
0.14
-0.05
-2.73
0.73
0.8
-2.3
-1.32
-0.61
0.82
-0.05
0.77
0.94
2.01
3.83
3.51
3.52
Free Cash Flow per Basic Share
0.24
0.12
0.13
0.18
0.04
-0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.32
Dividend per Share
14.32
14.62
15.31
15.86
15.64
15.17
11.41
9.5
8.33
8.19
8.53
8.86
9.71
10.18
10.63
10.98
11.77
Book Value per Share
14.08
13.95
14.04
7.7
9.78
5.44
0.51
0.82
2.86
3.07
3.44
3.77
4.66
5.14
5.5
5.79
6.06
Tangible Book Value per Share
36
36
36
36
44
44
60
79
117
123
123
123
123
123
123
123
123
Basic Weighted Avg Shares
3,133
2,934
3,233
3,470
3,449
3,465
4,085
4,101
4,271
4,801
5,481
6,413
7,816
8,662
10,154
11,451
12,489
Sales/Revenue/Turnover
2.19
2.14
2.61
2.08
0.5
1.49
2
-0.2
1.24
1.92
2.13
1.94
3.11
3.01
2.95
3.06
3.67
Operating Margin (%)
5
6
8
9
16
16
20
31
34
96
102
126
138
149
170
200
215
Depreciation Expense
34
26
41
20
-52
-21
-49
-113
-10
12
52
78
81
70
115
119
155
Net Income, GAAP
14.1
13.92
24.19
4.49
- -
- -
- -
- -
- -
44.44
- -
- -
- -
4.58
3.95
- -
13.47
Effective Tax Rate (%)
1.1
0.9
1.26
0.59
-1.51
-0.61
-1.2
-2.75
-0.23
0.25
0.95
1.22
1.03
0.81
1.13
1.04
1.24
Profit Margin (%)
569
628
609
592
565
455
536
69
541
520
940
865
1,024
1,093
1,031
1,009
1,552
Working Capital
75
98
84
335
235
187
362
41
344
497
666
740
802
845
888
975
1,127
LT Debt
519
541
571
572
689
668
759
746
1,021
1,005
1,435
1,476
1,511
1,539
1,586
1,636
1,685
Total Equity
9.15
8
5.56
1.93
- -
- -
- -
- -
- -
1.81
- -
- -
- -
9.32
10.15
- -
- -
Return on Invested Capital (%)
10.8
9.39
5.27
2.27
- -
- -
- -
- -
- -
3.58
- -
- -
- -
8.33
9.06
- -
- -
Return on Capital (%)
6.85
5.03
7.43
3.59
-8.26
-3.12
-6.86
-14.98
-1.1
1.18
5.1
7.33
7.1
5.77
8.98
8.98
- -
Return on Common Equity (%)

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
427
542
771
LT Borrowings
564
636
693
LT Finance Leases
411
421
434
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
123
123
123
Market Capitalization
1,119
1,014
834

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
4,494
4,266
5,713
Cash, Cash Equivalents & STI
235
317
488
Accounts Receivable, Net
1,556
1,610
2,367
Inventories
2,095
1,765
2,147
Total Current Liabilities
3,485
3,216
4,161
Payables & Accruals
- -
- -
- -
ST Debt
427
542
771
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.33%
2.65%
3.14%
Free Cash Flow
-238.74%
-299.51%
-8.26%
Net Income, GAAP
39.03%
21.28%
3.77%
Sales/Revenue/Turnover
12.87%
15.94%
12.77%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,251
2,283
2,604
3,016
10,154
2025
2,710
2,702
2,850
3,188
11,451
2026
2,874
3,577
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.23
0.4
0.29
0.93
2025
0.1
0.18
0.38
0.32
0.97
2026
-0.01
0.58
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
0.32
- -
- -
- -
- -
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Profarma Distribuidora de Produtos Farmacêuticos S.A. Profarma Distribuidora de Produtos Farmacêuticos S.A. engages in the distribution and retail of pharmaceutical products throughout Brazil. Founded in 1961 and headquartered in Rio de Janeiro, the company operates through three primary segments: wholesale pharmaceutical distribution, specialties, and retail pharmacy; it distributes prescription drugs, over-the-counter generics, personal hygiene articles, cosmetics, vaccines, dermatological products, and hospital pharmaceuticals to drugstores, hospitals, and clinics via 15 distribution centers across strategic regions including Rio de Janeiro, São Paulo, Northeast Brazil, and the Midwest. In its retail division, under the d1000 varejo farma banner, it manages over 200 stores operating as Drogasmil, Farmalife, Drogarias Tamoio, and Drogaria Rosário brands, offering medicines, personal care items, and exclusive private-label products such as Nº 21, GOnutri, Bem Básico, Bonnevi, Dfresh, Mini Moon, Mise, Polimix, and Wissen to consumers nationwide. The company expanded into retail in 2013 through acquisitions of Drogasmil, Farmalife, and Tamoio chains, followed by Rede Rosário in 2016; it formed a specialties joint venture with AmerisourceBergen Corporation in 2014, which culminated in the 2021 sale of its equity interest in the specialties segment to CM Hospitalar S.A., and completed the divestiture of Profarma Specialty S.A. in 2022 for gross proceeds of R$84.6 million from its minority stake. Recent developments include the 2023 launch of Próton, its innovation hub to foster health ecosystem partnerships with entrepreneurs and universities; the 2024 opening of a new distribution center in Mato Grosso to enhance Midwest operations; and ongoing recognition of Rede d1000 as Brazil's most efficient retail pharmacy chain per the IBEVAR ranking for two consecutive years through 2024, alongside the 2020 IPO of d1000 retail farma that raised R$400 million.